Eurofins
Eurofins is recorded as a service provider in 274 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 274 trials · Latest update first
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
Sponsor Merz Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Subjects were recruited at 10 investigative sites in Poland, Ukraine, and Türkiye.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Sponsor Aura Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor Ipsen Innovation
- Start (EU)
- Latest update
- Estimated end
A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine
Sponsor Merz Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine
Sponsor Merz Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.
Sponsor Aimmune Nestle Health Science US R&D LLC
- Start (EU)
- Latest update
- Estimated end
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Microdystrophin (GNT0004) Gene Therapy Clinical Trial in Duchenne Muscular Dystrophy: A phase I/II/III study with a dose determination part followed by an efficacy and safety evaluation, quadruple blind placebo-controlled part and then by a long term safety follow up part, in ambulant boys
Sponsor Genethon
- Start (EU)
- Latest update
- Estimated end
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtastasis (The REPOSE study)
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
Sponsor Galderma S.A.
- Start (EU)
- Latest update
- Estimated end
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 44 participants at five centers in France, Germany, and the United Kingdom.
- Protocol amendments modified inclusion criteria and added or clarified exclusion criteria.
- Protocol amendments increased the Part 1 sample size, added and omitted dose-escalation cohorts, and added pembrolizumab as study treatment.
These findings describe the trial, not the service provider’s performance or responsibility.
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
Sponsor Stealth Biotherapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants with Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn’s Disease
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
An exploratory double-blind randomized placebo-controlled trial to evaluate the effect of ARTENSIUM® cream in the relief of pain in patients with knee osteoarthritis
Sponsor Boiron
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Eurofins?
The 2026-10-09 snapshot links Eurofins to 274 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, Clinical monitoring, Data management, among 92 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Eurofins?
The most frequently recorded therapeutic areas are Immunology, Haematological Malignancies, Neurology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Eurofins conducted?
The linked trials record locations in 26 countries, including Spain, France, Germany, Italy, Poland. These are trial locations, not confirmed office locations or countries where Eurofins delivered services.
What can this page tell me about Eurofins's trial experience?
Browse 274 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 9 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 36 recorded name variants under Eurofins. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- EUROFINS DANMARK A/S
- EUROFINS MEGALAB, S.A.U.
- Eurofins Adme Bioanalyses
- Eurofins Advinus Biopharma Services India Pvt Ltd
- Eurofins Amatsi Analytics
- Eurofins Amatsigroup S.A.S.
- Eurofins Analytics & Services Austria GmbH
- Eurofins Bactimm B.V.
- Eurofins BioPharma Product Testing Biologics
- Eurofins BioPharma Product Testing Munich GmbH
- Eurofins BioPharma Product Testing Switzerland AG
- Eurofins Biolab S.r.l.
- Eurofins Biomnis
- Eurofins Biopharma Product Testing Denmark A/S
- Eurofins Central Laboratory B.V.
- Eurofins Central Laboratory LLC
- Eurofins Central Laboratory Pte Ltd
- Eurofins Central Laboratory Pte. Ltd
- Eurofins Clinical Diagnostics
- Eurofins Clinical Trial Supplies France
- Eurofins Danmark A/S
- Eurofins Genomics Europe AgriGenomics Products & Services A/S
- Eurofins Genomics Europe Applied Genomics GmbH
- Eurofins Genomics Europe Food/Environment/White Biotech Products & Services
- Eurofins Genomics Europe Genotyping A/S
- Eurofins Humangenetik und Praenatal-Medizin MVZ GmbH
- Eurofins Lancaster Laboratories Inc.
- Eurofins Lancaster Laboratories LLC
- Eurofins Megalab S.A.
- Eurofins Optimed
- Eurofins Panlabs Inc.
- Eurofins Pharma Bioanalytics Services US Inc.
- Eurofins Pharma Quality Control
- Eurofins Viracor Biopharma Services Inc.
- Eurofins Viracor Biopharma Services LLC
- Eurofins bioskin GmbH